June 30, 2026
EPS Corporation
Notice Regarding Business Restructuring and Trade Name Change of the Successor Company
— Weaving Data to Create New Value in Healthcare —
EPS Corporation (Headquarters: Tokyo; Representative Director: Noriyuki Takai; hereinafter "EPS"), a provider of development support services for pharmaceuticals, medical devices, and regenerative medicine products, has decided to implement a partial business restructuring to strengthen the competitiveness of its post-marketing and data businesses.
By integrating the post-marketing and data businesses, this restructuring aims to drive a transition to a data-driven business model, accelerating improvements in business competitiveness and the creation of new value. Under this restructuring, an absorption-type split will be executed with EP Mediate Co., Ltd. (hereinafter “EP Mediate”) as the successor company. Concurrently, EP Mediate will change its trade name to "EP-DataWeave Co., Ltd." (hereinafter "EP-DataWeave") and begin operations under this new structure.
Background and Objectives of the Restructuring
The EPS Group has prioritized establishing a next-generation business foundation and enhancing profitability as key themes under its medium-term management plan, "FUMIDASU2027." Its foundational business, EPNextS, Inc., which oversees the Groupʼs domestic business, is working to strengthen operations under the slogan “Forging a New Future” by accelerating digitalization, creating new services, and strengthening external collaborations.
Meanwhile, in the healthcare field, structural changes within the industry are accelerating. This transformation is driven by emerging challenges in clinical development, such as drug lag and drug loss, alongside the establishment of medical data infrastructure, the practical application of AI and other digital technologies, and advancements in international standardization and regulatory frameworks.
Against the backdrop of these environmental changes, several trends are progressing simultaneously: an increasing need for comprehensive support from the early stages of development, the expanded and more sophisticated utilization of data, advancements in digital technology, and deeper collaboration among domestic and international stakeholders.
Consequently, customer needs are becoming increasingly complex. In this environment, it has become essential to move beyond providing individual services and instead transition both clinical development and post-marketing businesses to a value-creating business model that offers comprehensive and cross-functional support. Furthermore, responding to the growing demand for data-driven business solutions has also become increasingly important.
This restructuring is designed to address these transitions, driving sophistication and strengthening international competitiveness in the clinical development field. At the same time, by integrating our post-marketing and data businesses, we aim to establish a sustainable competitive advantage.
Summary of the Absorption-type Split
(1)Method of the Split
This is an absorption-type split with EPS as the splitting company and EP Mediate as the successor company.
(2) Business to be Succeeded
The scope of the split covers each of the following businesses of EPS, as well as the planning, management, operations, and other ancillary duties necessary for the execution of said businesses:
・ Real World Evidence Business Division
・ Next Generation Solution Center
・ Drug Discovery Information Office
(3)Rights and Obligations to be Succeeded
Through this absorption-type split, the assets, contractual status, and related rights and obligations pertaining to the target businesses will be succeeded by the successor company.
(4)Change of Trade Name of the Successor Company
EP Mediate, the successor company, is scheduled to change its trade name to "EP-DataWeave Co., Ltd." on October 1, 2026.
(5) Scheduled Date of the Absorption-Type Split (Effective Date)
October 1, 2026 (Scheduled)
Role and Business Positioning of EP-DataWeave
As a core operating company responsible for delivering data-driven integrated solutions, EP-DataWeave will integrate its post-marketing business with its data business to provide seamless, cross-functional support across the post-marketing field.
・ Post-Marketing Surveillance (PMS) services
・ Pharmacovigilance (PV) services
・ Clinical Research Support services
・ Food & Healthcare Evidence Generation Support services
・ Real-world data utilization
・ Promotion of digital transformation (DX) leveraging data science
・ Other related businesses
Through these initiatives, rather than providing standalone services, EP-DataWeave will deliver data-driven integrated solution services, with a primary focus on the post-marketing field.
In addition, by connecting a diverse range of data and functions, both within and beyond the Group, EP-DataWeave will accelerate the creation of new value to drive the advancement of the healthcare industry.
Functions and Roles of EPS Post-Restructuring
Following this restructuring, EPS will continue to serve as the core of the Groupʼs foundational business, performing CRO*1 functions focused primarily on clinical development.
In recent years, clinical development led by emerging biotech companies both in Japan and overseas has accelerated, and CROs are now required to provide more comprehensive support than ever before. Against this backdrop, demand for the FSO (Full Service Outsourcing) model is also rising.
Leveraging its expertise cultivated through its strength in the FSP (Functional Service Provider) model, EPS will enhance its capability to support the FSO model.
At the same time, we will build a development support system with enhanced global-standard and full-service processes.
Through these efforts, we will provide comprehensive, total-solution services for the development of pharmaceuticals, medical devices, and regenerative medicine products, thereby driving value creation across the entire Group.
Vision of EP-DataWeave
EP-DataWeave has established the following vision:
“Weaving Data, Connecting People and Shaping Well-being”
The word "Weave" in the company name reflects EP-DataWeaveʼs commitment to integrating scattered data and transforming it into new value. By doing so, we aim to connect companies, medical institutions, and consumers, thereby contributing to the development of the entire healthcare ecosystem.
Future Outlook
EP-DataWeave will advance data-driven services, develop new business models, and promote strategic alliances to create new business opportunities. Through these initiatives, the company will enhance the competitiveness of its post-marketing business, while simultaneously creating new value and expanding business opportunities within the healthcare field through the power of data.
Overview of the Parties to the Corporate Restructuring
|
Splitting Company |
Successor Company |
| Company Name |
EPS Corporation |
EP Mediate Co., Ltd. |
| Headquarters Location |
Tsuruya Building, 2-23 Shimomiyabicho, Shinjuku-ku, Tokyo |
Acropolis Tokyo 8F, 6-29 Shin-Ogawacho, Shinjuku-ku, Tokyo |
| Registered Office Address |
Same as above |
TSUKUDO TERRACE, 2-1 Tsukudohachimancho, Shinjuku-ku, Tokyo |
| Representative Director |
Noriyuki TAKAI |
Masanori TANJI |
New Structure of the Successor Company
| Former Name |
EP Mediate Co., Ltd. |
| New Name |
EP-DataWeave Co., Ltd. |
| Effective Date |
October 1, 2026 |
| Headquarters Location |
Acropolis Tokyo 3F, 6-29 Shin-Ogawacho, Shinjuku-ku, Tokyo |
| Registered Office Address |
TSUKUDO TERRACE, 2-1 Tsukudohachimancho, Shinjuku-ku, Tokyo |
| Representative Director |
Takuya KUSABA (scheduled to assume office on October 1, 2026) |
In Closing
Through this restructuring, EPS and EP-DataWeave aim to enhance their agility in responding to environmental changes and strengthen their international competitiveness in the clinical development business. At the same time, the two companies will strengthen the competitiveness of the post-marketing and data businesses, while accelerating the creation of new value by connecting data and people.
The EPS Group will continue to contribute to the sustainable development of the healthcare industry by implementing its medium-term management plan, "FUMIDASU2027."
About EPS Corporation
EPS Corporation began operations in 1991 and is a leading CRO that provides comprehensive support for clinical trials and clinical research, with a focus on clinical development and post-marketing surveillance. The company proposes new models to meet customersʼ needs by leveraging its data science expertise and digital technologies cultivated through its extensive track record. These service offerings are anchored in its Trial GATE concept, which acts as the gateway for all clinical trial functions.
For media inquiries or further information, please contact:
EPS Corporation
Public Relations Department
E-mail: koho@eps.co.jp
※1 CRO︓Contract Research Organization
Contact Us
Share this page